Sean Nolan
2023
In 2023, Sean Nolan earned a total compensation of $1.5M as Chief Executive Officer and Director at Taysha Gene Therapies, a 20% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $324,000 |
|---|---|
| Option Awards | $597,184 |
| Salary | $600,000 |
| Other | $1,331 |
| Total | $1,522,515 |
Nolan received $600K in salary, accounting for 39% of the total pay in 2023.
Nolan also received $324K in non-equity incentive plan, $597.2K in option awards and $1.3K in other compensation.
Rankings
In 2023, Sean Nolan's compensation ranked 749th out of 2,647 executives tracked by ExecPay. In other words, Nolan earned more than 71.7% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 749 out of 2,647 | 72nd |
Division Manufacturing | 438 out of 1,447 | 70th |
Major group Chemicals And Allied Products | 304 out of 817 | 63rd |
Industry group Drugs | 297 out of 783 | 62nd |
Industry Biological Products, Except Diagnostic Substances | 95 out of 204 | 53rd |
Source: SEC filing on April 18, 2024.
Nolan's colleagues
We found two more compensation records of executives who worked with Sean Nolan at Taysha Gene Therapies in 2023.